Gilead Sciences announced in a press release Wednesday that its COVID-19 drug remdesivir reduces hospitalizations by 87% in high-risk patients.
The study consisted of 562 patients who were randomly given either remdesivir to a placebo. The company said that it saw an 87% reduction in hospitalizations after day 28, according to the press release. The trial was supposed to have over 1,000 subjects but the Gilead halted enrollment after other COVID-19 drugs became readily available.
The Daily Caller was founded in 2010 by Tucker Carlson, a 20-year veteran journalist, and Neil Patel, former chief policy advisor to Vice President Cheney, The Daily Caller is one of America’s largest and fastest-growing news publications. Our team of experienced, full-time reporters and editors works around the clock to deliver award-winning original reporting, in-depth investigations, entertainment, thought-provoking commentary and up-to-the-second breaking news. Visit https://dailycaller.com